Pepe (PEPE) is 252927.4× the size of Metformin (MET) by market capitalisation. Their daily returns move barely together (correlation 0.13 across 33 shared trading days). MET has been the more volatile of the two, at 198% annualised against PEPE's 102%.
METPEPE
0.13over 33 shared trading days
Measured on daily returns rather than on prices. Two assets that both simply trend upward score near 1.0 on raw prices whether or not they move together, so returns are what answer the question people mean by correlation.
| Metric | MET | PEPE |
|---|---|---|
| Max drawdown (400d) | -32.4% | -77.2% |
| Risk-adjusted return (90d) | -0.11 | 0.71 |
| Best 30 days (past year) | — | +63.5% |
| Worst 30 days (past year) | — | -48.9% |
Relative strength over 90 days: PEPE outperformed MET by 29.9% — measured on the MET/PEPE ratio, so it holds regardless of market direction.